Entries by BioSpace

, , ,

Baxter International Puts Down $900 Million to Beef Up Cancer Products for Spinoff

Deerfield, Ill.-based Baxter International (BAX) said Tuesday it would buy a promising leukemia treatment, Oncaspar, from Italian company Sigma-Tau Finanziaria S.p.A. for $900 million, as it bolsters its oncology pipeline in an increasingly lucrative and competitive field. Baxter estimated oncology alone could bring in $10 billion once its pipeline is established, with Oncaspar already raking […]

, ,

Pfizer Pays $87.5 Million for Stake in AM-Pharma, With Option to Swallow Entire Company

Pfizer Inc. (PFE) is continuing its buying spree, announcing late Monday that it has acquired a minority equity interest in Dutch biopharma AM-Pharma Holding BV in an attempt to add its acute kidney injury technology, recombinant human Alkaline Phosphatase (recAP), to its ever-growing specialty pipeline. It also snapped up an exclusive option to acquire the […]

, , ,

Endo Pharmaceuticals Shells Out $130 Million for Nearly 70 Pipeline Programs From Aspen Pharmacare Holdings

DUBLIN — Endo International (ENDP) has continued its trend of expanding its portfolio through acquisitions, announcing a $130 million deal to acquire a large portfolio of anti-pain anti-infectives, cardiovascular and other therapeutics areas from Aspen Pharmacare Holdings, the company said this morning. The deal includes products that are currently on the market, as well as […]

,

As Hampton Takes Over as Chairman at GlaxoSmithKline (GSK), CEO Witty Needs to Deliver or “Step Aside”

GlaxoSmithKline (GSK) is under scrutiny Tuesday, after more analysts have called for its longstanding chief executive, Sir Andrew Witty, to either step up his performance or resign within the next year, as the company prepares to receive its new chairman later this week. “Mr. Witty is running out of time,” said Stephen Bailey, a fund […]

, ,

Costco Accuses Johnson & Johnson (JNJ) of Price Fixing

Costco Wholesale Corp. filed a complaint in March against Johnson & Johnson (JNJ), accusing J&J’s Vision Care Inc. of price fixing related to its contact lenses. The suit was made public on Friday in J&J’s quarterly report to the U.S. Securities and Exchange Commission (SEC). J&J’s 10-Q filing has a laundry list of updates on […]

,

Celgene (CELG) Dealmaking Continues With Two Pacts Worth $110 Million With Northern Biologics, Agios (AGIO)

CAMBRDIGE, Mass. – Celgene Corporation (CELG) has struck two deals with other pharmaceutical companies with a combined value of $110 million to advance its oncology platform, continuing the cancer drugmaking company’s deal making trend to advance its oncology pipeline. Today Celgene announced it entered into an $80 million agreement with Agios Pharmaceuticals (AGIO) to develop […]

,

Celgene Picks Up San Francisco Biotech Quanticel in $485 Million Deal

SUMMIT, N.J. & SAN DIEGO—Celgene Corporation (CELG) struck a $485 million deal to acquire cancer drugmaking company Quanticel Pharmaceuticals, the company announced this morning. The deal between the two cancer specialists, has been nearly four years in the making, following a partnership established in 2011. The news of the acquisition sent Celgene’s stock up more […]